trial

Systematic Evaluation of Antiviral Medication in Schizophrenia

NCTId NCT00514449
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 31 (actual)
Sponsored by Konasale Prasad
Primary completion 2016-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
31 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2007-06
Primary completion
2016-09
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Valacyclovir

Sponsors

Konasale PrasadLead Sponsor
Stanley Medical Research InstituteCollaborator
Wayne State UniversityCollaborator

Investigators

4
Konasale Prasad, MDPrincipal Investigator
Vishwajit Laxmikant Nimgaonkar, MD PhDPrincipal Investigator
Matcheri S. Keshavan, MDPrincipal Investigator
Rajaprabhakaran Rajarethinam, MDPrincipal Investigator

Sites

2 total
Detroit, United StatesPittsburgh, United States

Linked catalysts

1
Systematic Evaluation of Antiviral Medication in Schizophrenia — primary completion2016-09

Facts & assertions

4 sourced
Enrollment
31
Phase
PHASE2
Primary Completion Date
2016-09
Status
COMPLETED
relationships
The graph out of here
drug
Valacyclovir
drug
lead_sponsor
Konasale Prasad
company
collaborator
Stanley Medical Research Institute
company
Wayne State University
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Konasale Prasad, MD
person
Vishwajit Laxmikant Nimgaonkar, MD PhD
person
Matcheri S. Keshavan, MD
person
Rajaprabhakaran Rajarethinam, MD
person